Symbols

OM

Outset Medical·NASDAQ

--(--)

OM fundamentals

OM Q4 2025 Earnings

Outset Medical (OM) released its earnings on Feb 11, 2026: revenue was 28.90M (YoY -2.03%), beat estimates; EPS was -0.84 (YoY +84.86%), missed estimates.

Revenue / YoY

28.90M

-2.03%

EPS / YoY

-0.84

+84.86%

Report date

Feb 11, 2026

OM Earnings Call Summary for Q4,2025

Revenue Growth: 5% YoY to $119.5M, driven by acute care partnerships and Tablo adoption.
FDA-Cleared Innovation: Next-gen Tablo is first dialysis system compliant with FDA's 2025 cybersecurity standards.
Gross Margin Expansion: 39.6% (non-GAAP) in 2025, targeting 50%+ in future years.
2026 Outlook: $125-130M revenue (5-9% growth), low-mid 40% gross margin, improving cash flow.
Clinical Impact: In-sourcing reduces CLABSI rates by 40% and length of stay by 1.5 days.

Earnings

EPS

Revenue

Revenue & Expenses

OM has released its 2025 Q4 earnings report, with revenue of 28.87M, reflecting a YoY change of -2.01%, and net profit of -19.49M, showing a YoY change of 23.98%. The Sankey diagram below clearly presents OM's revenue sources and cost distribution.

Key Indicators

Outset Medical (OM) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Outset Medical (OM)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Outset Medical (OM)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Outset Medical (OM)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown